Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
General eligibility criteria used in clinical trials: Adults aged 18 years or older BMI of 30 or higher (obesity), or BMI of 27 or higher with at least one weight-related health condition such as: Hypertension (high blood pressure) Dyslipidaemia (abnormal cholesterol levels) Obstructive sleep apnoea Cardiovascular disease At least one previous unsuccessful attempt at weight reduction through diet and exercise Who may not be suitable: Individuals with a personal or family history of medullary thyroid carcinoma Those with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) People with a known hypersensitivity to the medication Women who are pregnant, planning to become pregnant, or breastfeeding Individuals currently taking another GLP-1 receptor agonist medication Those who have had bariatric surgery or are planning surgical weight loss treatment A thorough medical consultation is necessary before starting treatment
Youre going as upstream as possible
He still checks in with me every few months
The phase III trial is scheduled to conclude in May 2026, with full results expected later that year
Reduced adipose tissue oxygenation in human obesity: evidence for rarefaction, macrophage chemotaxis, and inflammation without an angiogenic response
US$ 26.37
US$ 28.95
US$ 20.72
US$ 27.41
US$ 25.92
US$ 25.34
US$ 28.82
US$ 25.08
US$ 23.25
US$ 28.18
US$ 27.68
US$ 24.46
